TY - T1的诊断产量快速眼动睡眠肌肉活动的假定Synucleinopathy神经退化(N7.001) JF -神经学乔-神经学六世- 90 - 15补充SP N7.001 AU -斯图尔特McCarter盟约翰Feemster AU -格蕾首页丝Tabatabai盟大卫Sandness AU -保罗·蒂姆盟Allison McCarter盟-希瑟Talley AU -凯蒂·约翰逊盟Rodolfo Savica盟Prashanthi Vemuri AU -米歇尔Mielke盟-玛丽Machulda盟Kejal Kantarci AU -沃尔夫冈歌手盟-伊丽莎白浣熊AU -基思·约瑟夫AU -布拉德利Boeve AU -迈克尔·西尔柏AU - Erik圣路易斯Y1 - 2018/04/10 UR - //www.ez-admanager.com/content/90/15_Supplement/N7.001.abstract N2 -目的:确定障碍快速眼动睡眠没有弛缓(RSWA)区分临床诊断Synucleinopathy (SYN)和non-synucleinopathy (NSYN)认知障碍和/或帕金森症的病因。背景:神经退行性疾病的出现通常继发于两个proteinopathies;α-突触核蛋白[(帕金森病(PD)、多系统萎缩(MSA)和路易体痴呆(下文)]和τ[(阿尔茨海默氏痴呆(AD),额颞叶痴呆(FTD)进行性核上的麻痹(PSP)或corticobasal综合症(CBS)],虽然其他proteinopathies经常共存。症状重叠复杂精确临死前的诊断和额外的诊断工具来区分临床诊断SYN和NSYN病因是必要的。设计/方法:我们在138年分析定量RSWA病人;73 SYN (33 PD, 20 MSA, 20下文),50 NSYN(公元15、11 FTD 17 PSP 7 CBS),和15个主要控制打鼾。阶段,补药,“任何”肌肉活动百分比和相位的破裂时间计算在submentalis (SM)和前胫骨(AT)的肌肉。自动快指数也决定在SM。统计组进行了比较和回归和接受者操作特征曲线(ROC)用于确定RSWA达标,杰出的SYN NSYN。结果:所有RSWA措施明显更大的SYN患者。SM切断与AUC的在0.9(敏感性,特异性):“任何”11.5% (75%,96%);阶段的10.8% (75%,98%);相位的破裂时间0.61秒(74%,94%)。 In contrast, AT SYN discrimination was poor. Cutoffs were similar irrespective of clinical dream enactment behavior. Subgroup analysis showed greatest SM RSWA in patients with MSA, similar RSWA elevations in PD and DLB patients, and control level RSWA in AD, FTD, PSP and CBS patients.Conclusions: Quantitative submentalis REM sleep muscle activity accurately distinguished clinically diagnosed SYN from NSYN etiologies, even without clinical dream enactment. Polysomnographic RSWA appears to be a useful diagnostic tool for probable alpha-synucleinopathy in patients with parkinsonism and/or cognitive impairment.Study Supported by: This study was supported in part by a Mayo Clinic Alzheimer’s Disease Research Center Grant AG016574.Disclosure: Dr. McCarter has nothing to disclose. Dr. Feemster has nothing to disclose. Dr. Tabatabai has nothing to disclose. Dr. Sandness has nothing to disclose. Dr. Timm has nothing to disclose. Dr. McCarter has nothing to disclose. Dr. Talley has nothing to disclose. Dr. Hancock has nothing to disclose. Dr. Savica has nothing to disclose. Dr. Vemuri has nothing to disclose. Dr. Mielke has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly, Lysosomal Therapeutics, Inc. Dr. Machulda has nothing to disclose. Dr. Kantarci has nothing to disclose. Dr. Singer has nothing to disclose. Dr. Coon has nothing to disclose. Dr. Josephs has nothing to disclose. Dr. Boeve has received research support from GE Heathcare and Axovant. Dr. Silber has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UptoDate, Oakstone Publishing. Dr. St. Louis has nothing to disclose. ER -